Repligen shells out $150M for New Hampshire biotech By: Boston Business Journal via Business Journals September 16, 2021 at 13:17 PM EDT Waltham drug developer Repligen is paying $150 million in cash and stock to acquire a New Hampshire-based chromatography developer called Avitide Inc. Read More >>
